INTELLIA THERAPEUTICS INC (NTLA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NTLA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NTLA | Director | 74 | ["Director of the Center on Medical Product Access, Safety and Stewardship at Georgetown University","Infectious disease physician at the Washington D.C. Veterans Affairs and Walter Reed Medical Centers","Former chief scientist of the U.S. Food and Drug Administration (FDA)","Former deputy commissioner for science and public health at the FDA","Former director of the FDA’s Center for Biologics Evaluation and Research","Served on the board of directors of GlaxoSmithKline plc and BiomX, Inc.","Numerous advisory board and committees for national and international health care organizations"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Goodman served on the nominating and corporate governance committee throughout 2025 and on the science and technology committee throughout 2025, serving as committee chair of the science and technology committee. Our board of directors has determined that Dr. Goodman is independent as defined in the applicable Nasdaq rules.